Pradeep Singh, MD
Cardiovascular Disease · Rock Hill, SCNPI 1659327997
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,569 of the $6,617 with a category attached, or 84.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,368 and has fallen 58.7% since, to $566 in 2025.
Across 130 payments — averaging $50.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Artivion, Inc.$1K
- Boston Scientific$932
- E.r. Squibb & Sons, L.L.C.$623
- Novartis$403
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$302
- Merck$263
- plus $3K from 28 others
Across 217 payments — averaging $304.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$47K
- AstraZeneca$9K
- Amgen$7K
- Medtronic$3K
What the payments were for
- Speaking & faculty fees$1773%
- Travel & lodging$87213%
- Food & beverage$5,56984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Artivion, Inc. | 3 | $1,189 |
| Boston Scientific | 20 | $932 |
| E.r. Squibb & Sons, L.L.C. | 18 | $623 |
| Novartis | 17 | $403 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $302 |
| Merck | 9 | $263 |
| Abbott | 3 | $230 |
| Biotronik Inc. | 3 | $218 |
| Actelion Pharmaceuticals US, Inc. | 3 | $217 |
| Abiomed | 4 | $204 |
| Edwards Lifesciences | 3 | $194 |
| Novo Nordisk | 3 | $192 |
| Bayer | 3 | $158 |
| Penumbra, Inc. | 1 | $143 |
| Inspire Medical Systems, Inc. | 1 | $140 |
| Cardiovascular Systems Inc. | 2 | $130 |
| Scpharmaceuticals Inc. | 1 | $125 |
| Amarin Pharma, Inc. | 1 | $125 |
| Johnson & Johnson | 2 | $112 |
| Boehringer Ingelheim | 1 | $111 |
| Stability Biologics, LLC | 1 | $105 |
| Livanova USA, Inc. | 1 | $103 |
| Pfizer | 4 | $67 |
| Kestra Medical Technology Services, Inc. | 3 | $50 |
| Tactile Systems Technology Inc | 2 | $49 |
| Lexicon Pharmaceuticals, Inc. | 3 | $47 |
| AstraZeneca | 2 | $32 |
| Amgen | 2 | $29 |
| Medtronic(2 entities) | 2 | $27 |
| Getinge USA Sales, LLC | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Davol Inc. | 1 | $17 |
| Cleerly, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- On-X$872
- ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER$318
- WATCHMAN Access System$247
- CAMZYOS$238
- WATCHMAN FLX$164
- GENERAL MOLECULAR INTERVENTION$148
- Indigo System$143
- Inspire Upper Airway Stimulation System$140
- AVVIGO Guidance System$128
- Impella$127
- Vascepa$125
- FUROSCIX$125
- ENTRESTO$125
- CardioMEMS HF System$120
- Kerendia$120
- JARDIANCE$111
- Perceval$103
- XARELTO$103
- VERQUVO$100
How this compares
$6,617 in reported general payments places this provider in the 65th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 307 | $332,526 |
| XareltoRivaroxaban | 97 | $106,741 |
| FarxigaDapagliflozin Propanediol | 86 | $73,198 |
| EntrestoSacubitril/Valsartan | 53 | $71,887 |
| OzempicSemaglutide | 20 | $27,406 |
| Repatha SureclickEvolocumab | 33 | $24,517 |
| BrilintaTicagrelor | 31 | $23,342 |
| Praluent PenAlirocumab | 16 | $10,978 |
| Diovan HctValsartan/Hydrochlorothiazide | 13 | $5,488 |
| Metoprolol Succinate | 236 | $2,988 |
| Amlodipine Besylate | 427 | $2,478 |
| Rosuvastatin Calcium | 237 | $2,467 |
| ClopidogrelClopidogrel Bisulfate | 163 | $1,923 |
| Atorvastatin Calcium | 206 | $1,896 |
| Carvedilol | 246 | $1,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $332,526307 claims |
| Johnson & JohnsonXarelto | $112 | $106,74197 claims |
| AstraZenecaFarxiga, Brilinta | $32 | $96,540117 claims |
| NovartisEntresto | $403 | $71,88753 claims |
| Novo NordiskOzempic | $192 | $27,40620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Rock Hill
- Murad AbdelsalamRock Hill$21K
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
- James SmithCharleston$64K
- Christopher SalmonGreenville$54K
- Ricky HendersonAnderson$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.